Immune Thrombocytopenia epidemiology and demographics
Immune Thrombocytopenia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Immune Thrombocytopenia epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Immune Thrombocytopenia epidemiology and demographics |
FDA on Immune Thrombocytopenia epidemiology and demographics |
CDC on Immune Thrombocytopenia epidemiology and demographics |
Immune Thrombocytopenia epidemiology and demographics in the news |
Blogs on Immune Thrombocytopenia epidemiology and demographics |
Risk calculators and risk factors for Immune Thrombocytopenia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Barkhordarian, M.D.[2]
Overview
Epidemiology and Demographics
Incidence
- The incidence of Immune thrombocytopenia is approximately 1.6- 3.9 per 100,000 adult individuals worldwide and 1.1- 5.8 per 100,000 individuals among children. The overall incidence rate was higher in women (4.4 per 100,000 person year) than men ( 3.4 per 100,000 person year).
- In year 2014, the incidence of Immune thrombocytopenia among French people is approximately 2.9/ 100,000 person years with higher incidence among women. The incidence has bimodal distribution with first peak among male children among 1-5 years and men over 75 years of age. However the distribution for women is constant.[1] [2]
Prevalence
- The prevalence of chronic immune thrombocytopenia ( lasting longer than 12 months) is approximately 9.5-11.2 per 100,000 individuals in the United States.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
- Patients of all age groups may develop Immune thrombocytopenia.
- The Prevalence of chronic Immune thrombocytopenia increases with age; the childhood ITP remits spontaneously.
- Immune thrombocytopenia commonly affects individuals younger than 5 years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- [Disease name] affects men and women equally.
- Women are more commonly affected by Immune thrombocytopenia than men.
Season
- The majority of Immune thrombocytopenia cases are reported in January and the minority in summer in all age group probably due to viral infection..[1] [2]
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing Countries
References
- ↑ 1.0 1.1 Kohli, Rahil; Chaturvedi, Shruti (2019). "Epidemiology and Clinical Manifestations of Immune Thrombocytopenia". Hämostaseologie. 39 (03): 238–249. doi:10.1055/s-0039-1683416. ISSN 0720-9355.
- ↑ 2.0 2.1 Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes" Check
|url=
value (help). Biochem Pharmacol. 24 (17): 1639–41. PMID https://doi.org/10.1182/blood-2014-05-578336 Check|pmid=
value (help).